Cannabis Report
Home > Boards > US OTC > Biotechs >

U.S. Stem Cell Inc. (USRM)

Add USRM Price Alert      Hide Sticky   Hide Intro
Moderator: 4toSchool, Go-Gold, GoldenMind, Aces-DeucesMM, StemCellJunkie
Search This Board: 
Last Post: 6/18/2018 12:52:44 AM - Followers: 797 - Board type: Free - Posts Today: 1


US. Stem Cell, Inc. is committed to the discovery and development of autologous cellular therapies to treat a variety of degenerative diseases, as well as the continuation of our ongoing research for the treatment of heart failure, cardiovascular and perioheral vascular disease. 


The US. Stem Cell Inc. Vision
Our vision is to improve the quality of patients’ lives, while reducing hospitalizations and healthcare costs. 
Bioheart is and will continue to be recognized by physicians and patients as the world’s leader in providing 
innovative treatment and management of patients with severe cardiovascular and peripheral vascular 
disease. We are also focused on the discovery, development and commercialization of autologous cell therapies 
for the treatment of degenerative diseases.




Mike Tomás

President & CEO

Mike Tomas. Mr. Mike Tomas was appointed President and Chief Executive Officer and a member of our Board of Directors on June 19, 2010. Mike Tomas was appointed as the Company’s President and Chief Executive Officer, and as a director on June 19, 2010. Mr. Tomas has been President for the past nine years of The ASTRI Group, an early stage private equity investment company in Florida with an investment in Bioheart since 2001. In 2003, he joined Bioheart’s Board of Directors as the independent representative of The ASTRI Group. ASTRI provides capital, business development and strategic marketing support to emerging private companies. Mr. Tomas will continue to serve as President of The ASTRI Group. Previously from 1983 to 2001, Mr. Tomas held ascending executive positions including Chief Marketing Officer at Avantel, a $1 billion dollar joint venture with MCI. Upon retiring from MCI and WorldCom, Tomas joined other ex-MCI executives and helped raise $40M in venture capital to form Ineto, an integrated customer communications software solution that was successfully sold in 2001.
Mr. Tomas sits on the boards of Avisena (revenue cycle management company for medical practices), SilverSky (fka Perimeter Internetworking) (SaaS/managed security services provider for medical practices and financial institutions), Rokk3r Labs (a digital and mobile products developer and portfolio), Bioheart (adult stem cell development for heart muscle tissue repair) and is the current chairman of Florida International University’s Global Entrepreneurship Center. He is an inductee into the Miami-Dade College and WACE Halls of Fame for business, an FIU Torch Award winner — and winner of top communications, medical innovations, education and entrepreneurial awards. Mr. Tomas holds a Masters of Business Administration from the University of Miami and a Bachelor’s degree from Florida International University.

Kristin Comella

Chief Scientific Officer

Kristin Comella. Ms. Comella was appointed Chief Scientific Officer in September 2010. Ms. Comella has served as our Vice President of R&D and Corporate Development since December 2008 and has played a major role in managing our product development, manufacturing and quality systems since joining Bioheart in 2004. Ms. Comella has 15 years of industry experience with expertise in regenerative medicine, training and education, research and product development, and currently serves on multiple advisory boards in the stem cell arena. Ms. Comella has many years of cell culturing experience including building and managing the stem cell laboratory at Tulane University's Center for Gene Therapy and developing stem cell therapies for osteoarthritis at Osiris Therapeutics. Ms. Comella holds an M.S. in Chemical Engineering from The Ohio State University and a B.S. in Chemical Engineering from the University of South Florida.  On March 12, 2013, Kristin Comella was appointed to serve as a member of our Board of Directors.

Dr. William P. Murphy, Jr.

William P. Murphy, Jr., M.D. Dr. Murphy has served as a member of our Board of Directors since June 2003. Dr. Murphy founded Small Parts, Inc., a supplier of high quality mechanical components for design engineers, in 1964 and served as its Chairman until his retirement in April 2005. Small Parts, Inc. was acquired by, Inc. in March 2005. From October 1999 until October 2004, Dr. Murphy served as the Chairman and Chief Executive Officer of Hyperion, Inc., a medical diagnosis company which had an involuntary bankruptcy filed against it in December 2003. Dr. Murphy is the founder of Cordis Corporation (now Cordis Johnson & Johnson) which he led as President, Chairman and Chief Executive Officer at various times during his 28 years at Cordis until his retirement in October 1985. Cordis Johnson & Johnson is a leading firm in cardiovascular instrumentation. Dr. Murphy received an M.D. in 1947 from the University of Illinois and a B.S in pre-medicine from Harvard College in 1946. He also studied physiologic instrumentation at Massachusetts Institute of Technology, or MIT. After a two year rotating internship at St. Francis Hospital in Honolulu, he became a Research Fellow in Medicine at the Peter Bent Brigham Hospital in Boston where he was the dialysis engineer on the first clinical dialysis team in the United States. He continued as an Instructor in Medicine and then a research associate in Medicine at Harvard Medical School. Dr. Murphy is the author of numerous papers and owns 17 patents. He is the recipient of a number of honors, including the prestigious Lemelson-MIT Lifetime Achievement Award, the MIT Corporate Leadership Award, the Distinguished Service Award from North American Society of Pacing and Electrophysiology, and the Jay Malina Award from the Beacon Council of Miami, Florida. He is also a member of the Inventors Hall of Fame


Executive Officers and Directors

Set forth below is information regarding our executive officers and directors as of December 31, 2013

Mike Tomas 48 Director, President and Chief Executive Officer, Chief Financial Officer
William P. Murphy, Jr., M.D. 90 Director, Chairman of the Board
Mark P. Borman  59  Director
Gregory Knutson 59 Director
Kristen Comella  37 DirectorChief Scientific Officer
Sheldon T. Anderson 63 Director



About U.S. Stem Cell, Inc.

US Stem Cell, Inc. (formerly Bioheart, Inc.) is an emerging enterprise in the regenerative medicine / cellular therapy industry. We are focused on the discovery, development and commercialization of cell based therapeutics that prevent, treat or cure disease by repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function. We believe that regenerative medicine / cellular therapeutics will play a large role in positively changing the natural history of diseases ultimately, we contend, lessening patient burdens as well as reducing the associated economic impact disease imposes upon modern society.

Business Strategy

 Our principal objective is to become a leading regenerative medicine company that discovers, develops and commercializes novel, autologous cell therapies, and related devices, for the treatment and improved care of patients suffering from chronic and acute heart damage as well as lower limb ischemia. Our secondary objective is the discovery, development and commercialization of autologous cell therapies for the treatment of degenerative diseases.  The number of heart failure patients is expected to increase from 25 million worldwide today to over 50 million in five years. Our focus is on serving these patients. To achieve our primary objective, we plan to pursue the following strategies:

  • - Obtain initial regulatory approval of MyoCell and/or MyoCell SDF-1 by targeting patients with severe heart damage. 
    - Continue existing studies with adipose derived stem cells and endothelial progenitor cells.
    - Continue to develop our pipeline of cell-based therapies and related devices for the treatment of chronic and acute heart damage. 
    - Develop our sales and marketing capabilities. 
    - Continue to refine our MyoCell and MyoCell SDF-1 cell culturing processes.
    - Expand and enhance our intellectual property rights.
    - License, acquire and/or develop complementary products and technologies. 


    Sunrise, FL – April 10, 2017 – U.S. Stem Cell, Inc. (USRM), a Florida corporation and leader in novel regenerative medicine solutions and physician-based stem cell therapies for human and animal patients, has received reactivation status of the MARVEL phase II/III trial.

    Following the passing of the 21st Century Cures Act, U.S. Stem Cell, Inc. has applied to the FDA for Regenerative Medicine Advanced Therapy (RMAT) Designation for the MyoCell product as part of the MARVEL trial.  Our trial had previously been placed on “Inactive Status” as patients were not actively being enrolled.  We placed a request to the FDA to reactivate the protocol and consider the therapy for RMAT designation.  We have recently heard from the FDA who has notified us that the protocol has been placed on “Reactivation Status” after reviewing details on the protocol and data collected on patients to date.  The FDA has also notified us that they are still reviewing our submission for RMAT.  Thanks to the REGROW component of the Cures Act, The FDA will grant RMAT designation for a regenerative medicine therapy that is intended to treat, modify, reverse, or cure a serious or life-threatening disease and demonstrates preliminary clinical evidence that the product has the potential to address unmet medical needs for a disease.  We believe that our MyoCell product meets these requirements as we have demonstrated clinical efficacy in both preclinical and clinical studies including our most recent MARVEL trial publication (review full publication here:  If RMAT designation is granted, this could expedite the approval process with the FDA.

    More information on the FDA’s new RMAT Designation can be found here:

USRM - Daily Candlesticks

SUNRISE, Fla.Jan. 8, 2018 /PRNewswire/ -- U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced world-renowned fitness expert Ben Greenfield successfully received its stromal vascular fraction treatment for erectile enhancement.  Details of the procedure and the results are featured in the January issue of Men's Healthon newsstands now. Link here!!! ----->>>>

Ben Greenfield posted (Jan 16th, 2018) video at US Stem Cell clinic in Florida

Expecting Ben Greenfield's article to be found here once written any day now...

Press Releases:

Cannabis Report
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
USRM News: Statement of Changes in Beneficial Ownership (4) 05/18/2018 04:05:16 PM
USRM News: Statement of Changes in Beneficial Ownership (4) 05/18/2018 04:02:40 PM
USRM News: Quarterly Report (10-q) 05/09/2018 05:14:57 PM
USRM News: Small Company Offering and Sale of Securities Without Registration (d) 05/04/2018 04:37:37 PM
USRM News: Current Report Filing (8-k) 04/26/2018 04:50:25 PM
PlusOneCoin Top Posts
#95461   FDA/DOJ's Prosecutorial Misconduct Unmasked in Recent Publication Cryptofan 05/31/18 03:22:02 PM
#95686   Details on Tarek El Moussa's Back Procedure Cryptofan 06/07/18 12:48:25 PM
#95932   WHY IS USRM DELETING ALL VIDEO "TESTIMONIALS"...uh... Hornet Driver 06/13/18 11:32:14 AM
#94862  Sticky Note Is this how USRM says the FDA / Gobsmacked01 05/16/18 09:43:09 PM
#93850  Sticky Note USRM CUSTOMERS SPEAK! THE MEDICAL REVOLUTION IS HERE! sdave2002 05/06/18 12:53:21 PM
#85293  Sticky Note $USRM in 1 year has ~X3 Profits,~X2 revenues,~X4 GoldenMind 12/04/17 04:27:33 PM
#79439  Sticky Note BOARD WARNING: Please Read IH Geek [Dave] 09/14/17 12:53:48 PM
#96087   Chelby84 06/18/18 12:52:44 AM
#96086   UNITED STATES VS Comella/USRM...LAWSUIT FILED..SCATHING... Hornet Driver 06/17/18 10:25:33 PM
#96085   MARCH 1st, 2018..USRM IS UNDER SEC INVESTIGATION.... Hornet Driver 06/17/18 10:05:22 PM
#96084   TV NEWS FL: COMELLA FAMILY "OWNS" THE CLINIC..BEING SUED... Hornet Driver 06/17/18 10:03:54 PM
#96083   The FDA is toast. Just it that TruthSpeaker12 06/17/18 11:07:27 AM
#96081   I found and posted this link to the a1tellem 06/17/18 10:33:10 AM
#96080   A MUST READ. WHAT A WAY TO START yogi17 06/17/18 10:27:38 AM
#96077   Excellent link here Doc.. Really can not see Stubbornseller 06/17/18 09:40:03 AM
#96074 FDA o docprep 06/17/18 12:40:19 AM
#96073   Stem Cells and Cancer Gordon Research Conference BillyBahama 06/16/18 05:28:25 PM
#96072   2019 World Stem Cell Summit.. January 22-25, 2019 BillyBahama 06/16/18 05:27:19 PM
#96071   Will the FDA SLAM KC after they dismiss Lonewolf1 06/16/18 04:02:26 PM
#96069   I can afford to lose mine! Make or TruthSpeaker12 06/16/18 03:14:43 PM
#96068   Good post. FDA’s going to slam Comella and Disbelief1 06/16/18 02:56:38 PM
#96065   FDA's Regulation of Regenerative Medicine including Stem Cell BillyBahama 06/16/18 08:37:54 AM
#96064   Can’t wait for this! Great opportunity for the a1tellem 06/15/18 11:21:06 PM
#96063   Wired Magazine?? May as well be Cosmopolitan Mag - Lonewolf1 06/15/18 03:38:23 PM
#96062   Poke the Drone. kaos2k 06/15/18 02:47:59 PM
#96060   UNITED STATES VS Comella/USRM...LAWSUIT FILED..SCATHING... Hornet Driver 06/15/18 02:34:30 PM
#96059   More fake ness! $$IsEverything$$83 06/15/18 01:58:09 PM
#96058   WIRED Magazine: Comella/USRM ILLEGAL CANCER TREATMENTS NOW..? Hornet Driver 06/15/18 01:50:32 PM
#96057   Quote LOL, "From the SEC website: Hornet Driver 06/15/18 01:45:18 PM
#96056   From the SEC website: Cryptofan 06/15/18 01:24:37 PM
#96054   Gap fill soon Dmwcrash 06/15/18 11:48:48 AM
#96053   I love all the fake walls today, no Go-Gold 06/15/18 11:13:22 AM
#96052   WHERE DID "DALLAS" CLINIC AND SALLEY GO....?????? Hornet Driver 06/15/18 11:11:36 AM
#96051   Nothing will stop this from rising. USRM will $$IsEverything$$83 06/15/18 10:02:46 AM
#96049   MARCH 1st, 2018..USRM IS UNDER SEC INVESTIGATION.... Hornet Driver 06/15/18 09:30:25 AM
#96048   Could you imagine that pop when USRM wins $$IsEverything$$83 06/15/18 09:15:54 AM
#96046   NOT GETTING MINE! rocketRider 06/15/18 09:03:26 AM
#96045   We are golden here! $$IsEverything$$83 06/15/18 08:32:08 AM
#96044   Looks like a big nothing burger to me sdave2002 06/15/18 07:18:51 AM
#96043   It's all good and no worries. Lonewolf1 06/14/18 04:15:01 PM
#96042   0.0313 / 0.0325 (10000 x 10000) GOING NOWHERE... Hornet Driver 06/14/18 04:01:58 PM
#96040   Some group doing all they can to try MyzStreet 06/14/18 03:52:46 PM
#96039   looks like all of the view counts were TheReacher 06/14/18 03:52:22 PM
#96038   Non-sequitur. Also, did you read the first line TheReacher 06/14/18 03:49:56 PM
#96037   Deleting videos will have little if any effect Lonewolf1 06/14/18 03:49:53 PM
#96036   Ooo the good ol days ... someone find PistolPeteFan 06/14/18 02:42:43 PM
#96035   Yes, the video of John Salley was deleted Cryptofan 06/14/18 02:21:21 PM
#96032   Yes, the "Dark Forces" are trying from every Lonewolf1 06/14/18 01:54:19 PM
#96030   It would appear that a malicious actor worked Cryptofan 06/14/18 01:49:07 PM
#96029   My bad yes u are right !!!!! Moke31 06/14/18 01:47:15 PM
#96028   Days not over! Hippycowboy 06/14/18 01:46:20 PM
#96027   Quote LOL NO, "MORE FAKE NEWS : Testimonials Hornet Driver 06/14/18 01:46:14 PM
#96026   I thought we would be up again today !!!!! Moke31 06/14/18 01:38:20 PM
#96025   MORE FAKE NEWS : Testimonials are still there als money 06/14/18 01:38:11 PM
#96024   LOL They are BAKED AND DONE if you sdave2002 06/14/18 01:25:50 PM
#96023   Not worried! Future of medicine cures work and Stubbornseller 06/14/18 01:22:53 PM
#96022   UNITED STATES VS Comella/USRM...LAWSUIT FILED..SCATHING... Hornet Driver 06/14/18 01:17:11 PM